Eosinophils as a pharmacological target for the treatment of allergic diseases

Nadine Anna Caterina Landolina*, Francesca Levi-Schaffer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Eosinophils are innate immune cells and active players in inflammatory responses. Their activation and increased levels in the blood and at specific sites are associated with parasitic infections and several inflammatory conditions, notably allergic diseases in which eosinophils are considered to be damaging cells. Intervention targeting eosinophils is thought to prevent and/or limit irreversible organ damage and other eosinophil-associated disorders like hypereosinophilic syndromes, some cancers and autoimmune diseases. Several eosinophil-targeted therapeutic agents which block specific steps in eosinophil differentiation, migration and activation have recently been developed, showing encouraging results and new insights into their specific role in allergy. Here, we review some potentially effective drug compounds, their drawbacks and future prospective focusing on allergic diseases.

Original languageAmerican English
Pages (from-to)71-80
Number of pages10
JournalCurrent Opinion in Pharmacology
Issue number1
StatePublished - Aug 2014

Bibliographical note

Funding Information:
We acknowledge the support of the Aimwell Charitable Trust (UK), KAMIN ( Israel Ministry of Trade and Industry ) (grant #49041 ), and the Israel Science Foundation (grant #699/10 ).


Dive into the research topics of 'Eosinophils as a pharmacological target for the treatment of allergic diseases'. Together they form a unique fingerprint.

Cite this